Advancing cancer diagnosis and prognostication through deep learning mastery in breast, colon, and lung histopathology with ResoMergeNet.

IF 7 2区 医学 Q1 BIOLOGY
Chukwuebuka Joseph Ejiyi, Zhen Qin, Victor K Agbesi, Ding Yi, Abena A Atwereboannah, Ijeoma A Chikwendu, Oluwatoyosi F Bamisile, Grace-Mercure Bakanina Kissanga, Olusola O Bamisile
{"title":"Advancing cancer diagnosis and prognostication through deep learning mastery in breast, colon, and lung histopathology with ResoMergeNet.","authors":"Chukwuebuka Joseph Ejiyi, Zhen Qin, Victor K Agbesi, Ding Yi, Abena A Atwereboannah, Ijeoma A Chikwendu, Oluwatoyosi F Bamisile, Grace-Mercure Bakanina Kissanga, Olusola O Bamisile","doi":"10.1016/j.compbiomed.2024.109494","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer, a global health threat, demands effective diagnostic solutions to combat its impact on public health, particularly for breast, colon, and lung cancers. Early and accurate diagnosis is essential for successful treatment, prompting the rise of Computer-Aided Diagnosis Systems as reliable and cost-effective tools. Histopathology, renowned for its precision in cancer imaging, has become pivotal in the diagnostic landscape of breast, colon, and lung cancers. However, while deep learning models have been widely explored in this domain, they often face challenges in generalizing to diverse clinical settings and in efficiently capturing both local and global feature representations, particularly for multi-class tasks. This underscores the need for models that can reduce biases, improve diagnostic accuracy, and minimize error susceptibility in cancer classification tasks. To this end, we introduce ResoMergeNet (RMN), an advanced deep-learning model designed for both multi-class and binary cancer classification using histopathological images of breast, colon, and lung. ResoMergeNet integrates the Resboost mechanism which enhances feature representation, and the ConvmergeNet mechanism which optimizes feature extraction, leading to improved diagnostic accuracy. Comparative evaluations against state-of-the-art models show ResoMergeNet's superior performance. Validated on the LC-25000 and BreakHis (400× and 40× magnifications) datasets, ResoMergeNet demonstrates outstanding performance, achieving perfect scores of 100 % in accuracy, sensitivity, precision, and F1 score for binary classification. For multi-class classification with five classes from the LC25000 dataset, it maintains an impressive 99.96 % across all performance metrics. When applied to the BreakHis dataset, ResoMergeNet achieved 99.87 % accuracy, 99.75 % sensitivity, 99.78 % precision, and 99.77 % F1 score at 400× magnification. At 40× magnification, it still delivered robust results with 98.85 % accuracy, sensitivity, precision, and F1 score. These results emphasize the efficacy of ResoMergeNet, marking a substantial advancement in diagnostic and prognostic systems for breast, colon, and lung cancers. ResoMergeNet's superior diagnostic accuracy can significantly reduce diagnostic errors, minimize human biases, and expedite clinical workflows, making it a valuable tool for enhancing cancer diagnosis and treatment outcomes.</p>","PeriodicalId":10578,"journal":{"name":"Computers in biology and medicine","volume":"185 ","pages":"109494"},"PeriodicalIF":7.0000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Computers in biology and medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1016/j.compbiomed.2024.109494","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer, a global health threat, demands effective diagnostic solutions to combat its impact on public health, particularly for breast, colon, and lung cancers. Early and accurate diagnosis is essential for successful treatment, prompting the rise of Computer-Aided Diagnosis Systems as reliable and cost-effective tools. Histopathology, renowned for its precision in cancer imaging, has become pivotal in the diagnostic landscape of breast, colon, and lung cancers. However, while deep learning models have been widely explored in this domain, they often face challenges in generalizing to diverse clinical settings and in efficiently capturing both local and global feature representations, particularly for multi-class tasks. This underscores the need for models that can reduce biases, improve diagnostic accuracy, and minimize error susceptibility in cancer classification tasks. To this end, we introduce ResoMergeNet (RMN), an advanced deep-learning model designed for both multi-class and binary cancer classification using histopathological images of breast, colon, and lung. ResoMergeNet integrates the Resboost mechanism which enhances feature representation, and the ConvmergeNet mechanism which optimizes feature extraction, leading to improved diagnostic accuracy. Comparative evaluations against state-of-the-art models show ResoMergeNet's superior performance. Validated on the LC-25000 and BreakHis (400× and 40× magnifications) datasets, ResoMergeNet demonstrates outstanding performance, achieving perfect scores of 100 % in accuracy, sensitivity, precision, and F1 score for binary classification. For multi-class classification with five classes from the LC25000 dataset, it maintains an impressive 99.96 % across all performance metrics. When applied to the BreakHis dataset, ResoMergeNet achieved 99.87 % accuracy, 99.75 % sensitivity, 99.78 % precision, and 99.77 % F1 score at 400× magnification. At 40× magnification, it still delivered robust results with 98.85 % accuracy, sensitivity, precision, and F1 score. These results emphasize the efficacy of ResoMergeNet, marking a substantial advancement in diagnostic and prognostic systems for breast, colon, and lung cancers. ResoMergeNet's superior diagnostic accuracy can significantly reduce diagnostic errors, minimize human biases, and expedite clinical workflows, making it a valuable tool for enhancing cancer diagnosis and treatment outcomes.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Computers in biology and medicine
Computers in biology and medicine 工程技术-工程:生物医学
CiteScore
11.70
自引率
10.40%
发文量
1086
审稿时长
74 days
期刊介绍: Computers in Biology and Medicine is an international forum for sharing groundbreaking advancements in the use of computers in bioscience and medicine. This journal serves as a medium for communicating essential research, instruction, ideas, and information regarding the rapidly evolving field of computer applications in these domains. By encouraging the exchange of knowledge, we aim to facilitate progress and innovation in the utilization of computers in biology and medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信